The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Which emerging therapeutic approaches have the potential to transform patient outcomes in MF?
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, shares insights into emerging therapeutic approaches with the potential to transform patient outcomes in myelofibrosis (MF), highlighting favorable results with selinexor, navtemadlin, and pelabresib from the SENTRY (NCT04562389), POIESIS (NCT06479135), and MANIFEST-2 (NCT04603495) trials, respectively. Dr Mascarenhas emphasizes the importance of understanding how to best use these agents to improve patient outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
